Curated News
By: NewsRamp Editorial Staff
October 28, 2026
VolitionRx Signs LOI with Missionpharma to Develop NETosis Lateral Flow Test
TLDR
- VolitionRx's LOI with Missionpharma opens global commercialization for its NETosis lateral flow test, targeting neonatal sepsis in underserved markets.
- VolitionRx's finger-prick lateral flow test measures circulating nucleosomes and neutrophil extracellular traps to detect NETosis-related inflammation like neonatal sepsis.
- VolitionRx and Missionpharma aim to bring affordable neonatal sepsis diagnostics to low-income countries, improving early detection and saving lives.
- VolitionRx's lateral flow prototype for NETosis showed high correlation with its automated Nu.Q NETs test in critically ill sepsis patients.
Impact - Why it Matters
This collaboration could accelerate access to affordable, point-of-care diagnostics for neonatal sepsis in low- and middle-income countries, where early detection is critical. By leveraging Missionpharma’s distribution networks and low-cost manufacturing, Volition’s lateral flow technology may enable timely intervention and improve outcomes for vulnerable populations. The partnership also validates Volition’s epigenetic platform and opens new markets for its Nu.Q NETs technology.
Summary
VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, has signed a nonbinding letter of intent with Denmark-based Missionpharma A/S to explore the development and global commercialization of its prototype lateral flow technology (LFT) for detecting NETosis, a process linked to inflammation. The collaboration will initially focus on evaluating a finger-prick diagnostic test for neonatal sepsis, with potential applications in low- and middle-income countries and humanitarian emergency settings. Missionpharma, which supplies healthcare products to United Nations agencies, government health ministries, and other institutions, could support low-cost manufacturing, clinical studies, and distribution.
The agreement follows Volition’s recent announcement that results from its lateral flow prototype demonstrated high correlation with its established automated Nu.Q NETs test in critically ill sepsis patients. The technology measures circulating nucleosomes and neutrophil extracellular traps as potential early indicators of hyperinflammation, with applications extending beyond centralized laboratory testing. Volition believes the collaboration could accelerate access to affordable diagnostic tools in resource-constrained regions, where early identification and management of neonatal sepsis remain critical challenges. To view the full press release, visit: https://nnw.fm/9AltW
About Volition: Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
The contents found at Volition’s website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries: Ellen Amonoo, Volition, [email protected]
For further information, visit the company’s website at https://volition.com/
About NetworkNewsWire: NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
[email protected]
NetworkNewsWire is powered by IBN
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, VolitionRx Signs LOI with Missionpharma to Develop NETosis Lateral Flow Test
